Pralnacasan, an orally administered small molecule inhibitor of the interleukin-1β converting enzyme (ICE), demonstrates the potential for treating osteoarthritis in mice models by reducing caspase activity [151]. This evidence concerns the gene CASP1 and osteoarthritis.